AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN).

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.

Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb proof-of-concept trials.

The trial of Fintepla in Dravet Syndrome and LGS was run by researchers at the Brno Epilepsy Centre in Czechia.

Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m.

Anixa Biosciences has secured patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.

Experts at HLTH Europe 2026 agreed that healthcare innovations won't meet their full potential until healthcare services can implement them.

Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce.

Sobi has received a CRL from the US FDA regarding its BLA for NASP, an investigational therapy intended for adults with uncontrolled gout.

The European Medicines Agency (EMA) has recommended that marketing authorisation for Tavneos (avacopan) be revoked due to a question mark over the integrity of clinical data used to support its ...